Business Description
Alnylam Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US02043Q1076
Compare
Compare
Traded in other countries / regions
ALNY.USA0HD2.UKA1LN34.BrazilDUL.GermanyALNY.Mexico IPO Date
2019-06-14Description
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.14 | |||||
| Equity-to-Asset | 0.01 | |||||
| Debt-to-Equity | 40.24 | |||||
| Debt-to-EBITDA | -15.19 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 3.57 | |||||
| Beneish M-Score | -2.66 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 50.6 | |||||
| 3-Year EBITDA Growth Rate | 34.2 | |||||
| 3-Year EPS without NRI Growth Rate | 28.3 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 23.48 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 100 | |||||
| 9-Day RSI | 100 | |||||
| 14-Day RSI | 100 | |||||
| 6-1 Month Momentum % | 105.06 | |||||
| 12-1 Month Momentum % | 66.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.75 | |||||
| Quick Ratio | 2.69 | |||||
| Cash Ratio | 2.28 | |||||
| Days Inventory | 104.56 | |||||
| Days Sales Outstanding | 57.08 | |||||
| Days Payable | 83.93 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.6 | |||||
| Shareholder Yield % | 0.04 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 85.37 | |||||
| Operating Margin % | -8.98 | |||||
| Net Margin % | -15.86 | |||||
| FCF Margin % | 1.4 | |||||
| ROA % | -8.43 | |||||
| ROIC % | -18.55 | |||||
| 3-Year ROIIC % | -1015.46 | |||||
| ROC (Joel Greenblatt) % | -26.01 | |||||
| ROCE % | -6.41 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 16.34 | |||||
| PB Ratio | 1075.42 | |||||
| Price-to-Tangible-Book | 1080.53 | |||||
| Price-to-Free-Cash-Flow | 2347.22 | |||||
| Price-to-Operating-Cash-Flow | 617.69 | |||||
| EV-to-EBIT | -178.39 | |||||
| EV-to-Forward-EBIT | 582.42 | |||||
| EV-to-EBITDA | -389.05 | |||||
| EV-to-Forward-EBITDA | 289.89 | |||||
| EV-to-Revenue | 15.91 | |||||
| EV-to-Forward-Revenue | 12.67 | |||||
| EV-to-FCF | 2075.42 | |||||
| Price-to-Median-PS-Value | 0.22 | |||||
| Earnings Yield (Greenblatt) % | -0.56 | |||||
| FCF Yield % | 0.05 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alnylam Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 37,670.969 | ||
| EPS (TTM) (MXN) | -47.046 | ||
| Beta | -0.97 | ||
| Volatility % | 88.77 | ||
| 14-Day RSI | 100 | ||
| 14-Day ATR (MXN) | 32.30774 | ||
| 20-Day SMA (MXN) | 5464.845 | ||
| 12-1 Month Momentum % | 66.13 | ||
| 52-Week Range (MXN) | 2453 - 5899.69 | ||
| Shares Outstanding (Mil) | 128.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alnylam Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alnylam Pharmaceuticals Inc Stock Events
| Event | Date | Price(MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
Alnylam Pharmaceuticals Inc Frequently Asked Questions
What is Alnylam Pharmaceuticals Inc(MEX:ALNY)'s stock price today?
The current price of MEX:ALNY is MXN5899.69. The 52 week high of MEX:ALNY is MXN5899.69 and 52 week low is MXN2453.00.
When is next earnings date of Alnylam Pharmaceuticals Inc(MEX:ALNY)?
The next earnings date of Alnylam Pharmaceuticals Inc(MEX:ALNY) is 2025-02-14 Est..
Does Alnylam Pharmaceuticals Inc(MEX:ALNY) pay dividends? If so, how much?
Alnylam Pharmaceuticals Inc(MEX:ALNY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers